Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01603212 · ClinicalTrials.gov registry record · Phase 1
Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT01603212: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT01603212 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 6 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01603212, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The goal of the Phase I part of this clinical research study is to find the highest tolerable dose of vemurafenib and Aldesleukin (interleukin-2) that can be given in combination with interferon alfa-2b in patients with advanced or metastatic melanoma. The safety of this combination will also be studied. The goal of Phase II is to learn if this study drug combination can help to control advanced or metastatic melanoma.
Interventions
- DRUG IL-2
- DRUG Vemurafenib
- DRUG Interferon Alpha-2b
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2013-07-18 |
| Est. Completion | 2017-07-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01603212
The ClinicalTrials.gov registry entry for NCT01603212 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which IL-2 is the first listed.
NCT01603212 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01603212 about?
NCT01603212 is a clinical study titled "Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor". The goal of the Phase I part of this clinical research study is to find the highest tolerable dose of vemurafenib and Aldesleukin (interleukin-2) that can be given in combination with interferon alfa-2b in patients with advanced or metastatic melanoma. The safety of this combination will also be stu...
What is the current status of trial NCT01603212?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2013-07-18. Estimated completion is 2017-07-05.
What interventions are being tested in trial NCT01603212?
The interventions under investigation include: IL-2 (DRUG), Vemurafenib (DRUG), Interferon Alpha-2b (DRUG).
Who is sponsoring clinical trial NCT01603212?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.